Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoniazid monotherapy to prevent chronic kidney disease progression in latent tuberculosis infection
ISRCTN11515835Phase 4Recruiting
- Sponsor
- Kidney Foundation Hospital and Research Institute
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of isoniazid and pyridoxine in latent tuberculosis infection (LTBI) and chronic kidney disease (CKD) (2 arms), sponsored by Kidney Foundation Hospital and Research Institute. Primary endpoint: Rate of change in renal function. Started Jan 2024; status: recruiting.
02
Drugs
isoniazidpyridoxine
03
Conditions
latent tuberculosis infection (LTBI)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ISRCTN11515835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11515835.